SAN
DIEGO, Nov. 28, 2023 /PRNewswire/ -- DiCello
Levitt LLP announces that purchasers or acquirers of FMC
Corporation (NYSE: FMC) common stock between November 1, 2022 and October 30, 2023, inclusive (the "Class Period")
have until January 8, 2023, to seek
appointment as lead plaintiff of the FMC class action lawsuit. The
lawsuit charges FMC and certain of its senior executive officers
with violations of the Securities Exchange Act of 1934.
If you purchased or otherwise acquired shares of FMC common
stock between November 1, 2022 and
October 30, 2023, inclusive, and
suffered substantial losses, and you wish to serve as lead
plaintiff in this lawsuit, you may submit your information here:
https://dicellolevitt.com/securities/fmc-corporation/.
You can also contact DiCello Levitt partner Brian O'Mara by calling (888) 287-9005 or at
investors@dicellolevitt.com.
No Class Has Been Certified. Until a class is certified, you are
not represented by counsel unless you retain one. You may select
counsel of your choice. You may also remain an absent class member
and do nothing at this point. An investor's ability to share in any
potential future recovery is not dependent upon serving as lead
plaintiff.
Allegations
FMC is an agricultural sciences company specializing in the
production of patented crop protection products. According to
the FMC class action lawsuit, FMC relies upon its various patents
and other intellectual property to defend against competition,
generate revenue, and support its market position.
The FMC class action lawsuit alleges that
defendants throughout the Class Period made false and/or misleading
statements and/or failed to disclose that: (1) FMC had diminished
patent protection as a result of the loss of key legal disputes
over its patents in India; (2) as
a result of such losses, competitors were selling generic diamide
products in India; (3) FMC had
misleadingly downplayed the effect of rulings from China's Patent Office invalidating certain key
FMC patents in the country; (4) generic competitors of FMC in
Brazil had won important
regulatory approvals and could potentially sell generic products as
soon as the second half of 2023; (5) numerous competitors were
manufacturing and selling generic versions of FMC's top selling
insecticide product in India and
China at much lower prices than
being charged by FMC; and (6) FMC was unable to raise prices on its
branded diamide products to grow revenues or margins in its key
markets.
About DiCello Levitt
At DiCello Levitt, we are dedicated to achieving justice for our
clients through class action, business-to-business, public client,
whistleblower, personal injury, civil and human rights, and mass
tort litigation. Our lawyers are highly respected for their ability
to litigate and win cases – whether by trial, settlement, or
otherwise – for people who have suffered harm, global corporations
that have sustained significant economic losses, and public clients
seeking to protect their citizens' rights and interests. Every day,
we put our reputations – and our capital – on the line for our
clients.
DiCello Levitt has achieved top recognition as Plaintiffs Firm
of the Year and Trial Innovation Firm of the Year by the
National Law Journal, in addition to its top-tier
Chambers and Benchmark ratings. The New York
Law Journal also recently recognized DiCello Levitt as a
Distinguished Leader in trial innovation. For more information
about the Firm, including recent trial victories and case
resolutions, please visit www.dicellolevitt.com.
Attorney Advertising. Prior results do not guarantee a similar
outcome.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dicello-levitt-llp-announces-investor-class-action-lawsuit-filed-against-fmc-corporation-nyse-fmc-and-lead-plaintiff-deadline-301998540.html
SOURCE DiCello Levitt LLP